Merck’s Novel Vioxx Settlement May Set Standard To Resolve Litigation
Merck crafted extraordinary terms in its $4.85 billion agreement to resolve the bulk of Vioxx litigation, which analysts are heralding as a good result for the company
You may also be interested in...
Ranitidine Litigation Opens With Settlements, But Still Massive With State And MDL Trials Pending
GSK and Sanofi will continue to defend against all claims alleging ranitidine increased risk of cancer. Four Rx generic firms reach settlements in first case scheduled for trial. Former US OTC Zantac marketers GSK and Sanofi, which markets the Zantac OTC brand in the US, along with former Rx brand marketer Pfizer could pay $1bn to $2bn each in potential settlements, analyst predicts.
Massive Zantac Product Liability Litigation Advances After Initial Settlements
GlaxoSmithKline will continue to defend itself against all claims alleging ranitidine increased the risk of cancer. Four generic firms reach settlements in the first case that had been scheduled for trial. GSK, Sanofi and Pfizer could pay $1bn-$2bn each in potential settlements, an analyst predicts.
Tremeau Will Soon Test Rofecoxib In Phase III Hemophilia Joint Pain Trial
The company is developing the once-controversial drug formerly marketed as Vioxx under the name TRM-201 for hemophilia arthropathy with $110m in financing to support its program.